Alexandria Real Estate Equities
VC Fund
Pasadena, United States
Alexandria Real Estate Equities is a VC fund in Pasadena focused on Biotechnology and Health Care. Alexandria Real Estate Equities, Inc., Landlord of Choice to the Life Science Industry®, is the largest owner and pre-eminent first-in-class real estate investment trust focused principally on science-driven cluster formation. Alexandria is the leading provider of real estate to the life science industry, and has an outstanding 11 year trackrecord as a NYSE listed company with an approximate $5.2 billion total market capitalization (as of December 31, 2008).
- Total investments:
- 57
- Last investment:
- Lead investor:
- 4%
Last updated:
For AI agents: llms.txt
Industries Alexandria Real Estate Equities invests in
Stages Alexandria Real Estate Equities invests in
Countries Alexandria Real Estate Equities invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 13 contacts → | |||
Investment Focus
Industry
- Biotechnology 36 (63%)
- Health Care 22 (39%)
- Therapeutics 15 (26%)
- Medical 12 (21%)
- Pharmaceutical 10 (18%)
Stage
- Series A 18 (32%)
- Series B 16 (28%)
- Series C 7 (12%)
- Funding Round 6 (11%)
- Series D 3 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
John J. Cox
Senior Vice President
|
Senior Vice President | Total investments: 0 | Find email | |
Steven Hash
Board of Director
|
Board of Director | Total investments: 0 | Find email | |
Daniel J. Ryan
Executive Vice President
|
Executive Vice President | Total investments: 0 | Find email | |
| CFO | Total investments: 0 | Find email | ||
|
Hallie Kuhn
Vice President
|
Vice President | Total investments: 1 | Find email | |
| See all 13 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Mediar Therapeutics is a biotechnology company that develops antibody-based medicines and biologic therapies to address cancer, autoimmune diseases, and other serious health conditions. Its research platform focuses on engineering multi-specific antibodies and modular biologics that can engage multiple biological targets or pathways simultaneously,enabling precise modulation of immune responses. The company’s pipeline includes therapeutic candidates designed to activate or inhibit specific immune functions, with the goal of improving clinical outcomes in oncology and immune-mediated disorders. Mediar Therapeutics also works on scalable manufacturing processes and collaborates with scientific partners to advance its biologics from discovery through clinical development. Its approach integrates protein engineering, immunology, and translational research to create biologic medicines that address complex disease mechanisms. The company continues to refine its technology and expand its therapeutic programs to support future clinical and regulatory progress. | $76M / Series B / Jan 07, 2026 | ||
| TFC Therapeutics is a biotechnology company developing novel biologics to target and eliminate key drivers of cancer. | Seed / Aug 17, 2023 | ||
| Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). The company’s resorted platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels andactivity. Stablix initially is leveraging the platform to develop programs to treat rare diseases, cancer, and immunological disorders. | $63M / Series A / Jun 03, 2021 | ||
| C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations.The cancer intelligence company is developing a platform that can perform whole-genome sequencing using only 2 milliliters of blood. Its ultra-sensitive liquid biopsy assay allows physicians to monitor patient treatment response and detecttreatment failure or disease recurrence months and potentially years earlier than current monitoring methods. C2i’s cancer diagnostics service uses artificial intelligence pattern recognition and the whole-genome analysis to spot trace amounts of cancer much quicker, in about a week, to inform better treatment decisions and ultimately save lives. The company aims to help patients avoid unnecessary overtreatment with toxic chemotherapy or radiation, as well as to prevent them from going without treatment while cancer quietly grows and metastasizes.In 2019, Boris Oklander, Asaf Zviran, and Ezra Sofer established the company in New York, New York. | $100M / Series B / Apr 15, 2021 | ||
| TerMir is an innovative AgTech company that offers pioneering solutions to address key, unresolved agronomic and environmental challenges. | $100K / Grant / Jul 02, 2020 | ||
| At Cradle Genomics, their mission is to provide knowledge that helps every pregnancy. They're dedicated to the transformation of non-invasive prenatal testing (NIPT) by offering the most comprehensive fetal genetic analysis and pregnancy health screening solutions at the earliest stages of pregnancy. Cradle Genomics is newly formed with theirheadquarters based in San Diego and additional R&D operations located in Detroit. Cradle tests are based on the genetic analysis of fetal cells that are quickly collected during a first trimester visit with no risk to the mother or developing fetus. | $17.1M / Series A / Jul 16, 2019 | ||
| Strand Therapeutics is a developer of a biotechnology platform intended to create gene therapies powered by synthetic biology.The company's offerings include immunotherapies to help cells produce target cancer-killing proteins during immunotherapy, enabling patients to improve their body's immune system to fight cancer. | $6M / Seed / Jun 04, 2019 | ||
| Halio is transforming glass into responsive, intelligent, beautiful architectural elements that transition from clear to tinted to dark – automatically or on command. We're transforming architecture and design by offering a much more versatile architectural element for windows, walls, and skylights.We're transforming buildings andhomes to be more efficient, beautiful, and comfortable.Most importantly, we're transforming lives by giving people unprecedented comfort and control of their indoor environments and more connection to the outside world, while creating inspiring spaces for living and working.We’re doing it through technology. Halio technology is so advanced that we don’t call it electrochromic. Though it does tint when it receives an electrical charge, Halio tints up to 10x faster, it tints uniformly (no more iris or curtain effect), it looks like natural clear glass (no more honey hues), it tints to classic, neutral shades of gray (no more smurf blue), and finally, we give you unlimited tint level options. It's why we thought it needed to be called "smart-tinting glass."And that’s just the glass itself. Our software and hardware controls are best-of-class – and they’re designed to work seamlessly with building management/automation systems.Beyond performance, our manufacturing techniques result in yields that match the flat panel display industry – and that means on-time deliveries, no matter where in the world your project is located. | $100M / Series D / Jan 30, 2019 | ||
| Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissueselectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types. | $16M / Series B / Oct 17, 2018 | ||
| KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays inmultiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015. | $80M / Series C / Sep 28, 2018 | ||
| See all 57 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Alexandria Real Estate Equities invest in?
Alexandria Real Estate Equities invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 57 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alexandria Real Estate Equities?
Public channels for Alexandria Real Estate Equities include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Alexandria Real Estate Equities?
The team at Alexandria Real Estate Equities includes John J. Cox (Senior Vice President), Steven Hash (Board of Director) and Daniel J. Ryan (Executive Vice President), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
